148 related articles for article (PubMed ID: 35152500)
21. Personalized Therapy: Immunoglobulin Replacement for Antibody Deficiency.
Wasserman RL
Immunol Allergy Clin North Am; 2019 Feb; 39(1):95-111. PubMed ID: 30466775
[TBL] [Abstract][Full Text] [Related]
22. Features and outcomes of immunoglobulin therapy in patients with Good syndrome at Thailand's largest tertiary referral hospital.
Thongngarm T; Boonyasiri A; Pradubpongsa P; Tesavibul N; Anekpuritanang T; Kreetapirom P; Sompornrattanaphan M
Asian Pac J Allergy Immunol; 2019 Jun; 37(2):109-115. PubMed ID: 29888926
[TBL] [Abstract][Full Text] [Related]
23. Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate.
Castelli R; Vismara A; Pavia G; Dagani R; Porro T
Ann Ital Med Int; 2002; 17(1):47-50. PubMed ID: 11975114
[TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin replacement therapy by self-infusion at home.
Chapel H; Brennan V; Delson E
Clin Exp Immunol; 1988 Jul; 73(1):160-2. PubMed ID: 3168330
[TBL] [Abstract][Full Text] [Related]
25. Surface phenotype and immunoglobulin levels in B-cell chronic lymphocytic leukaemia.
Orfao A; Gonzalez M; San Miguel JF; Tomas JF; Canizo MC; Lopez-Berges MC; Moraleda JM; Lopez Borrasca A
Haematologia (Budap); 1990; 23(1):49-56. PubMed ID: 2397923
[TBL] [Abstract][Full Text] [Related]
26. Chronic lymphocytic leukaemia masquerading as a labial lump.
Lim WH; Mayson E; Lamaro VP
BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30642861
[TBL] [Abstract][Full Text] [Related]
27. Tolerability and kinetics of a solvent-detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients.
Ebeling F; Baer M; Hormila P; Järventie G; Koistinen P; Kätkä K; Oksanen K; Perkkiö M; Ruutu T; Soppi E
Vox Sang; 1995; 69(2):91-4. PubMed ID: 8585206
[TBL] [Abstract][Full Text] [Related]
28. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors.
Griffiths H; Brennan V; Lea J; Bunch C; Lee M; Chapel H
Blood; 1989 Feb; 73(2):366-8. PubMed ID: 2492832
[TBL] [Abstract][Full Text] [Related]
29. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.
Colado A; Elías EE; Sarapura Martínez VJ; Cordini G; Morande P; Bezares F; Giordano M; Gamberale R; Borge M
Sci Rep; 2021 Jun; 11(1):12926. PubMed ID: 34155276
[TBL] [Abstract][Full Text] [Related]
31. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis.
Raanani P; Gafter-Gvili A; Paul M; Ben-Bassat I; Leibovici L; Shpilberg O
Leuk Lymphoma; 2009 May; 50(5):764-72. PubMed ID: 19330654
[TBL] [Abstract][Full Text] [Related]
32. The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL).
Best OG; Crassini K; Freeman JA; Mulligan SP;
Scand J Infect Dis; 2013 Sep; 45(9):729. PubMed ID: 23826794
[No Abstract] [Full Text] [Related]
33. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma.
Sklenar I; Schiffman G; Jønsson V; Verhoef G; Birgens H; Boogaerts M; Ferrant A; Christensen BE; Hasle H; Drivsholm A
Oncology; 1993; 50(6):466-77. PubMed ID: 8233289
[TBL] [Abstract][Full Text] [Related]
34. The immunodeficiency of chronic lymphocytic leukaemia.
Hamblin AD; Hamblin TJ
Br Med Bull; 2008; 87():49-62. PubMed ID: 18755702
[TBL] [Abstract][Full Text] [Related]
35. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
36. Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia.
Spaner DE; Venema R; Huang J; Norris P; Lazarus A; Wang G; Shi Y
EBioMedicine; 2018 Sep; 35():222-232. PubMed ID: 30174282
[TBL] [Abstract][Full Text] [Related]
37. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
[TBL] [Abstract][Full Text] [Related]
38. Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?
Dhalla F; Lucas M; Schuh A; Bhole M; Jain R; Patel SY; Misbah S; Chapel H
J Clin Immunol; 2014 Apr; 34(3):277-82. PubMed ID: 24557494
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
